Olmesartan Impurities

Olmesartan is used primarily to treat hypertension as monotherapy or in fixed dose combinations to achieve blood pressure control and reduce cardiovascular risk associated with uncontrolled high blood pressure.

Avoid pregnancy, concurrent use of potassium supplements or potassium sparing diuretics without monitoring because of hyperkalemia risk, and avoid sudden volume depletion; use caution with NSAIDs which may reduce renal function when combined with renin angiotensin system blockers and monitor electrolytes and renal function as advised by a prescriber.

Olmesartan is not inherently nephrotoxic for most patients but it can reduce glomerular filtration pressure in settings such as bilateral renal artery stenosis, severe volume depletion or when combined with other drugs that affect renal perfusion, so renal function should be monitored and therapy adjusted if serum creatinine rises significantly.

Olmesartan as a molecule remains approved and available, but specific product lots or brand formulations may be discontinued for business, manufacturing or regulatory reasons including recalls, safety signal reviews or litigation; rare safety reports such as sprue like enteropathy prompted safety communications rather than a global class withdrawal, and discontinuations are typically product specific rather than a reflection that the active ingredient is universally withdrawn.